References
- Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, . Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51–131.
- Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193–204.
- Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–7.
- Weis M. Clinical review of hereditary angioedema: diagnosis and management. Postgrad Med. 2009;121:113–20.
- Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161: 2417–29.
- Bracho FA. Hereditary angioedema. Curr Opin Hematol. 2005;12:493–8.
- Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19: 147–51.
- Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:314–20.
- Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407–14.
- Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498–503.
- Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104: 211–4.
- Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, . HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22.
- Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9:189–90.
- Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, . 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24.
- De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29:247–54.
- Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, . Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523–31.
- Kalbitor prescribing information. Available from: http://www.kalbitor.com/pdf/KalbitorFullPrescribingInformation.pdf (accessed 15 July 2011).
- Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, . Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124: 801–8.
- Wasserman RL, Levy RJ, Bewtra AK, Hurewitz D, Craig TJ, Kiessling PC, . Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2011;106:62–8.
- Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, . Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513–22.
- Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, . Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821–7.e14.
- Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, . Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363: 532–41.
- Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, . Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529–37.
- Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, . EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523–9.
- Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, . C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139:379–94.
- Cyklokapron summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/16512/SPC/ (accessed 17 August 2011).
- Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, . International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308–20.
- Cinryze summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001207/WC500108895.pdf (accessed 15 July 2011).
- Berinert prescribing information. Available from: http://www.berinert.com/docs/Berinert_pi.pdf (accessed 15 July 2011).
- Cetor summary of product characteristics. Available from: http://www.sanquin.nl/sanquin-eng/sqn_products_plasma.nsf/All/F197E/$FILE/common-spc-summaryofproductcharacteristicscetor500uen.pdf (accessed 15 July 2011).
- Ruconest summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001223/WC500098542.pdf (accessed 15 July 2011).
- Firazyr summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf (accessed 15 July 2011).
- Craig T, Katelaris C, Longhurst H, Grumach A, Maurer M. Hereditary angioedema worldwide epidemiology and treatment practices: interim results of a WAO survey. Allergy. 2011;66(Suppl 94):1–104. (Abstract no. 164).
- Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, . Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67:147–57.
- Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol. 2011;106:316–22.e4.
- Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol. 2007;147:11–17.
- Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117:904–8.
- Rusicke E, Martinez-Saguer E, Aygören-Pürsün E, Kreuz W. Home treatment in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 2006;117:S180. (Abstract no. 700).
- Gabriel J. Infusion therapy. Part two. Prevention and management of complications. Nurs Stand. 2008;22:41–8.
- Dagen C, Craig TJ. Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol. 2010;6:11.